{"prompt": "['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', '17', 'Ethics', '17.1 Regulatory and Ethics Compliance', 'The study will be conducted in accordance with applicable laws and regulations including, but', 'not limited to, the Medicinal Products Act (Arzneimittelgesetz AMG) (1), the ICH E6 guideline', '(2) and the ethics principles that have their origins in the Declaration of Helsinki (3). The', 'protocol and the proposed ICFs have been reviewed and approved by a properly-constituted', 'ethics committee before study start. Prior to study start, the investigator is required to sign a', 'protocol signature page confirming his / her agreement to conduct the study in accordance', 'with these documents and all of the instructions and procedures found in this protocol and to', 'give access to all relevant data and records to monitors, auditors, IRBs / IECs, and regulatory', 'authorities as required. If an inspection of the clinical site is requested by a regulatory authority,', 'the investigator must inform the sponsor or its designee immediately that this request has been', 'made.', '17.2 Informed Consent', 'Informed consent of patients will be obtained in accordance with applicable laws and', 'regulations including, but not limited to, the Medicinal Products Act (Arzneimittelgesetz AMG)', 'and ICH E6 guideline by the investigator and / or his / her sub-investigator(s) personally prior', 'to each inclusion of a patient to the study.', 'The nature, objective and importance of the study, the possible benefits and disadvantages or', 'risks and the study procedures will be explained to each patient orally and in writing by each', 'investigator and / or his / her sub-investigators personally before the patient is to sign the', 'informed consent. The patients will also be informed', 'that their participation is voluntary', 'that they are free to withdraw from the study at any time', \"that choosing not to participate would not impact on the patient's care or future\", 'treatment', 'that, by signing the ICF, they explicitly permit access to their personal data', 'relating to study by authorized representatives of the sponsor and the regulatory', 'authorities without violating the confidentiality of the patient, to the extent', 'permitted by the applicable law(s) and / or regulations. The patients will also be', 'informed that their consent for use / analyse their already elevated data may not', 'be revoked by withdrawing from the trial.', 'Each patient will be given sufficient time to read and discuss the ICF with the investigator and', '/ or his / her sub-investigator(s) in person prior to giving his / her written consent. An oral', 'consent or written consent given via email or fax is not sufficient. Before entry to the study and', 'prior to the conduct of any study-related procedures consent will be recorded by means of the', \"patient's dated signature. The ICF will be signed two times. The patient is then given one (1)\", 'original of the information sheet and his / her signed consent form. The other original is filed in', 'the investigator site file at site. The collection of AE information will start at baseline visit.', 'A separate ICF will be prepared and consent obtained from patients willing to provide skin', 'biopsy samples for the purposes of this study.', 'Page 59 of 75']['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', '17.3 Amendments to the Protocol', 'Any substantial change or addition to the protocol can only be made in a written protocol', 'amendment that must be approved by the sponsor and, where required, regulatory authorities', 'and the IRB / IEC. Only amendments that are required for patient safety may be implemented', 'prior to IRB / IEC approval.', 'Notwithstanding the need for approval of formal protocol amendments, the investigator is', 'expected to take any immediate action required for the safety of any patient included in this', 'study, even if this action represents a deviation from the protocol. In such cases, the sponsor', 'or its designee should be notified of this action and the site-specific IRB / IEC should be', 'informed within 10 working days.', '17.4 Confidentiality', 'All involved sites have to confirm that they handle the information available in the documents', 'handed over strictly in confidence.', 'The process of collecting patient information will comply with the standards for protection of', 'privacy by applicable local / regional / national requirements for patient confidentiality. All', \"records will kept confidential and the patient's name will not be released at any time.\", 'Throughout this study all data will not to be released to anyone other than the sponsor /', 'sponsor delegates or representatives of the responsible government agencies, if requested.', \"Caution will be exercised to guarantee patient's confidentiality.\", 'In the event that a potential violation of Data Protection Regulations is detected, the following', 'measures will be implemented: as soon as the situation becomes known immediate action will', 'be taken to remediate the violation and a full investigation will be carried out to identify whether', 'any other subjects are at risk and to ensure appropriate corrective actions are implemented to', 'ensure that the situation does not recur.', 'Page 60 of 75']\n\n###\n\n", "completion": "END"}